Citius Oncology Secures $36.5 Million to Accelerate LYMPHIR Commercialization
Event summary
- Citius Oncology secures up to $36.5 million in debt and equity financing to support LYMPHIR commercialization.
- Avenue Capital Group provides up to $25 million via a senior credit facility, with an initial $10 million tranche funded at closing.
- Concurrent warrant exercise by a healthcare-focused institutional investor brings in approximately $11.5 million in gross proceeds.
- Financings aim to support sales force expansion, market access initiatives, and manufacturing supply chain support for LYMPHIR.
- LYMPHIR, approved by the FDA for relapsed or refractory Stage I-III cutaneous T-cell lymphoma, launched in the U.S. in December 2025.
The big picture
Citius Oncology's $36.5 million financing round underscores the strategic importance of LYMPHIR in the targeted oncology space. The deal reflects confidence from Avenue Capital Group in Citius Oncology's commercial trajectory and the long-term potential of LYMPHIR. The financings will support the company's efforts to expand patient access to this important therapy for relapsed or refractory cutaneous T-cell lymphoma, addressing a growing and underserved market.
What we're watching
- Commercial Execution
- How Citius Oncology will scale its commercial infrastructure and drive adoption of LYMPHIR among treating physicians.
- Financial Flexibility
- Whether the combined financings will provide sufficient capital to support ongoing commercialization efforts and future growth initiatives.
- Revenue Milestones
- The pace at which Citius Oncology achieves predefined revenue milestones to unlock additional tranches under the credit facility.
Related topics